Jiangsu Wanrong Biomedical Technology

Jiangsu Wanrong Biomedical Technology is a Chinese biotechnology company specializing in the development of next-generation oncolytic virus therapies for oncology. A subsidiary of Jiangsu Wanbang Biopharmaceutical Group (Fosun Pharma), the company was founded in 2019 and is headquartered in Xuzhou, Jiangsu Province. Its core technology is the Ad5MixPlus platform, a three-plasmid oncolytic adenovirus recombinant packaging system designed for the rapid and accurate production of therapeutic viruses. The company's lead candidate, VT-101, is an engineered oncolytic adenovirus that expresses a combination of immune-stimulating transgenes, including Interleukin-12, Interferon-gamma, and C-C motif chemokine ligand 5, to enhance anti-tumor immune responses. VT-101 is currently undergoing Phase 1 clinical trials for the treatment of non-muscle invasive bladder cancer and is being evaluated for other advanced solid tumors. The company leverages the manufacturing and commercialization infrastructure of its parent organization, Fosun Pharma, to advance its pipeline of gene-modified viral therapeutics.